TY - JOUR
T1 - Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan
T2 - Interim analysis of a multicentre cohort study
AU - Kashiwado, Yusuke
AU - Kimoto, Yasutaka
AU - Sawabe, Takuya
AU - Irino, Kensuke
AU - Nakano, Shota
AU - Hiura, Junki
AU - Wang, Qiaolei
AU - Kawano, Shotaro
AU - Ayano, Masahiro
AU - Mitoma, Hiroki
AU - Ono, Nobuyuki
AU - Arinobu, Yojiro
AU - Niiro, Hiroaki
AU - Hotta, Taeko
AU - Kang, Dongchon
AU - Akashi, Koichi
AU - Ohshima, Shiro
AU - Takeuchi, Tsutomu
AU - Horiuchi, Takahiko
N1 - Publisher Copyright:
© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2023/3/2
Y1 - 2023/3/2
N2 - OBJECTIVES: To evaluate the impact of medication on antibody response to severe acute respiratory syndrome coronavirus-2 mRNA vaccines in Japanese patients with rheumatic diseases. METHODS: This prospective multicentre cohort study evaluated the humoral response in 12 different medication groups. Antibody levels before the first vaccination and 3-6 weeks after the second vaccination were measured using the Elecsys Anti-SARS-CoV-2 S assay. Statistical analysis included comparing antibody titres among the different medication groups using the Kruskal-Wallis test followed by the Bonferroni-Dunn test and multiple linear regression analysis. RESULTS: 295 patients were analysed. The seroconversion rate was 92.2% and the median antibody titre was 255 U/ml (interquartile range, 34.1-685) after the second mRNA vaccination. Antibody levels were significantly lower in the groups treated with Tumour necrosis factor inhibitor with methotrexate, abatacept, mycophenolate mofetil (MMF), MMF or mizoribine combined with calcineurin inhibitor, and rituximab or cyclophosphamide compared with those treated with sulfasalazine and/or bucillamine or calcineurin inhibitor (p < 0.01). The correlation between antibody titre and treatment was significant after adjusting for age, gender, and glucocorticoid dose (p < 0.01). CONCLUSIONS: Additional early vaccination is required in patients treated with Tumour necrosis factor inhibitor and methotrexate, abatacept, MMF, MMF or mizoribine combined with calcineurin inhibitor and rituximab or cyclophosphamide.
AB - OBJECTIVES: To evaluate the impact of medication on antibody response to severe acute respiratory syndrome coronavirus-2 mRNA vaccines in Japanese patients with rheumatic diseases. METHODS: This prospective multicentre cohort study evaluated the humoral response in 12 different medication groups. Antibody levels before the first vaccination and 3-6 weeks after the second vaccination were measured using the Elecsys Anti-SARS-CoV-2 S assay. Statistical analysis included comparing antibody titres among the different medication groups using the Kruskal-Wallis test followed by the Bonferroni-Dunn test and multiple linear regression analysis. RESULTS: 295 patients were analysed. The seroconversion rate was 92.2% and the median antibody titre was 255 U/ml (interquartile range, 34.1-685) after the second mRNA vaccination. Antibody levels were significantly lower in the groups treated with Tumour necrosis factor inhibitor with methotrexate, abatacept, mycophenolate mofetil (MMF), MMF or mizoribine combined with calcineurin inhibitor, and rituximab or cyclophosphamide compared with those treated with sulfasalazine and/or bucillamine or calcineurin inhibitor (p < 0.01). The correlation between antibody titre and treatment was significant after adjusting for age, gender, and glucocorticoid dose (p < 0.01). CONCLUSIONS: Additional early vaccination is required in patients treated with Tumour necrosis factor inhibitor and methotrexate, abatacept, MMF, MMF or mizoribine combined with calcineurin inhibitor and rituximab or cyclophosphamide.
UR - http://www.scopus.com/inward/record.url?scp=85149427212&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149427212&partnerID=8YFLogxK
U2 - 10.1093/mr/roac030
DO - 10.1093/mr/roac030
M3 - Article
C2 - 35411376
AN - SCOPUS:85149427212
SN - 1439-7595
VL - 33
SP - 367
EP - 372
JO - Modern Rheumatology
JF - Modern Rheumatology
IS - 2
ER -
